
Please try another search
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
An-bang Lu | 57 | 2018 | CEO & Executive Director |
Hong Ni | 53 | 2021 | Independent Non-Executive Director |
Peng Kuan Chan | 61 | 2021 | Independent Non-Executive Director |
Shan Fu | 56 | 2018 | Non-Executive Chairman |
Zhengbin Yao | 59 | 2021 | Independent Non-Executive Director |
Michael J. Chang | 41 | 2023 | Non-Executive Director |
Yibo Cao | 43 | 2021 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review